Abstract Background There are now a growing number of licensed biological therapies for patients with Crohn’s disease (CD) but given the costs long-term maintenance treatment, as well some concerns about potential side effects, there has been increasing interest in elective treatment discontinuation selected patients, after period sustained remission. Following discontinuation, cases relapse, l...
